Beyond the numbers in treating hypertensive end-organ damage: role of formyl peptide receptor agonist Cmpd17b.

Autor: Albritton CF; Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, 560 Preston Cancer Research Building, 2220 Pierce Ave, Nashville, TN 37232, USA.; Department of Biomedical Sciences, School of Graduate Studies, Meharry Medical College, Nashville, TN 37208-3501, USA., Hinton A; Department of Molecular Physiology & Biophysics, Vanderbilt University, 750 Robinson Research Building, 2200 Pierce Ave, Nashville, TN 37232-0615, USA., Kirabo A; Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, 560 Preston Cancer Research Building, 2220 Pierce Ave, Nashville, TN 37232, USA.; Department of Molecular Physiology & Biophysics, Vanderbilt University, 750 Robinson Research Building, 2200 Pierce Ave, Nashville, TN 37232-0615, USA.; Vanderbilt Center for Immunobiology, 1211 Medical Center Drive, Nashville, TN 37232-0615, USA.; Vanderbilt Institute for Infection, Immunology and Inflammation, 1161 21st Ave South Medical Center North A-5121, Nashville, TN 37232-0615, USA.; Vanderbilt Institute for Global Health, 2525 West End Avenue, Suite 750, Nashville, TN 37203, USA.
Jazyk: angličtina
Zdroj: Cardiovascular research [Cardiovasc Res] 2024 Sep 21; Vol. 120 (11), pp. 1239-1240.
DOI: 10.1093/cvr/cvae134
Abstrakt: Competing Interests: Conflict of interest: none declared.
Databáze: MEDLINE